Status:
UNKNOWN
Transfusion of Red Blood Cells for Acute Respiratory Distress Syndrome(ARDS) in Neonates
Lead Sponsor:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Conditions:
Red Blood Cells(RBC)
Acute Respiratory Distress Syndrome (ARDS)
Eligibility:
All Genders
30-1 years
Phase:
NA
Brief Summary
Acute respiratory distress syndrome (ARDS) in neonates has been defined in 2017. The death rate is over 50%.There are no special treatments for acute respiratory distress syndrome.
Detailed Description
Acute respiratory distress syndrome (ARDS) is one of the serious complications in critically ill neonates. It can result in severe hypoxemia refractory to mechanical ventilation. There are few options...
Eligibility Criteria
Inclusion
- diagnosed with neonatal ARDS.
- informed parental consent has been obtained
Exclusion
- major congenital malformations or complex congenital heart disease
- transferred out of the neonatal intensive care unit without treatment
Key Trial Info
Start Date :
October 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03296059
Start Date
October 1 2017
End Date
December 1 2024
Last Update
October 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Chongqing, Chongqing Municipality, China, 400042